## Emerging EZH2 Inhibitors and Their Application in Lyn

Current Hematologic Malignancy Reports 13, 369-382 DOI: 10.1007/s11899-018-0466-6

Citation Report

#	Article	IF	CITATIONS
1	Small-Molecule Inhibitors for the Treatment of Diffuse Large B Cell Lymphoma. Current Hematologic Malignancy Reports, 2018, 13, 356-368.	2.3	14
2	Comprehensive Genomic Profiling of EBV-Positive Diffuse Large B-cell Lymphoma and the Expression and Clinicopathological Correlations of Some Related Genes. Frontiers in Oncology, 2019, 9, 683.	2.8	33
3	BET and EZH2 Inhibitors: Novel Approaches for Targeting Cancer. Current Oncology Reports, 2019, 21, 13.	4.0	27
4	Novel Therapies in Paediatric NHL. , 2019, , 315-335.		0
5	Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy. Trends in Immunology, 2019, 40, 328-344.	6.8	160
6	The EZ-riding NK/T-cell lymphoma. Blood, 2019, 134, 1999-2000.	1.4	1
7	EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications. Journal of Hematology and Oncology, 2019, 12, 118.	17.0	62
8	Targeting EZH2 Enhances Antigen Presentation, Antitumor Immunity, and Circumvents Anti–PD-1 Resistance in Head and Neck Cancer. Clinical Cancer Research, 2020, 26, 290-300.	7.0	142
9	β-TRCP-mediated AEBP2 ubiquitination and destruction controls cisplatin resistance in ovarian cancer. Biochemical and Biophysical Research Communications, 2020, 523, 274-279.	2.1	15
10	Knockdown of GAS5 Inhibits Atherosclerosis Progression via Reducing EZH2-Mediated ABCA1 Transcription in ApoEâ^'/â^' Mice. Molecular Therapy - Nucleic Acids, 2020, 19, 84-96.	5.1	68
11	Loss of histone lysine methyltransferase EZH2 confers resistance to tyrosine kinase inhibitors in non-small cell lung cancer. Cancer Letters, 2020, 495, 41-52.	7.2	17
12	The <i>HMGA1-pseudogene7</i> shows oncogenic activity <i>in vivo</i> . Cell Cycle, 2020, 19, 2955-2959.	2.6	3
13	Molecular Genetics of Relapsed Diffuse Large B-Cell Lymphoma: Insight into Mechanisms of Therapy Resistance. Cancers, 2020, 12, 3553.	3.7	22
14	Deregulation of Polycomb Repressive Complex-2 in Mantle Cell Lymphoma Confers Growth Advantage by Epigenetic Suppression of cdkn2b. Frontiers in Oncology, 2020, 10, 1226.	2.8	7
15	Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies. Journal of Hematology and Oncology, 2020, 13, 103.	17.0	69
16	EZH2-Targeted Therapies in Cancer: Hype or a Reality. Cancer Research, 2020, 80, 5449-5458.	0.9	139
17	Triplet Therapy with PD-1 Blockade, Histone Deacetylase Inhibitor, and DNA Methyltransferase Inhibitor Achieves Radiological Response in Refractory Double-Expressor Diffuse Large B-cell Lymphoma with 17p Deletion. Case Reports in Hematology, 2020, 2020, 1-6.	0.4	7
18	Tazemetostat: First Approval. Drugs, 2020, 80, 513-521.	10.9	198

	Сітатіоі	CITATION REPORT	
#	Article	IF	CITATIONS
19	Hypomethylating Agents in Lymphoma. Current Treatment Options in Oncology, 2020, 21, 61.	3.0	5
20	Epigenetic Therapies for Osteoarthritis. Trends in Pharmacological Sciences, 2020, 41, 557-569.	8.7	39
21	Epigenetic memory in development and disease: Unraveling the mechanism. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1873, 188349.	7.4	25
22	EZH2 inhibitors restore epigenetically silenced CD58 expression in B-cell lymphomas. Molecular Immunology, 2020, 119, 35-45.	2.2	28
23	The relationship between consumption of nitrite or nitrate and risk of non-Hodgkin lymphoma. Scientific Reports, 2020, 10, 551.	3.3	6
24	Impact and Intricacies of Bone Marrow Microenvironment in B-cell Lymphomas: From Biology to Therapy. International Journal of Molecular Sciences, 2020, 21, 904.	4.1	13
25	Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas. Immunity, 2021, 54, 116-131.e10.	14.3	72
26	Development of molecular intervention strategies for B-cell lymphoma. Expert Review of Hematology, 2021, 14, 241-252.	2.2	0
27	USP21 promotes cell proliferation by maintaining the EZH2 level in diffuse large B ell lymphoma. Journal of Clinical Laboratory Analysis, 2021, 35, e23693.	2.1	11
28	Targeting leukemia stem cells in T-cell acute lymphoblastic leukemia (T-ALL). , 2021, , 161-197.		0
29	Targeting Leukemia-Initiating Cells in Acute Lymphoblastic Leukemia. Cancer Research, 2021, 81, 4165-4173.	0.9	4
30	Potential of enhancer of zeste homolog 2 inhibitors for the treatment of SWI/SNF mutant cancers and tumor microenvironment modulation. Drug Development Research, 2021, 82, 730-753.	2.9	5
31	Genetic Impairments of PRC2 Activity in Oncology: Problems and Prospects. Russian Journal of Genetics, 2021, 57, 258-272.	0.6	5
32	Full methylation of H3K27 by PRC2 is dispensable for initial embryoid body formation but required to maintain differentiated cell identity. Development (Cambridge), 2021, 148, .	2.5	11
33	Free energy perturbation in the design of EED ligands as inhibitors of polycomb repressive complex 2 (PRC2) methyltransferase. Bioorganic and Medicinal Chemistry Letters, 2021, 39, 127904.	2.2	10
34	Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduction and Targeted Therapy, 2021, 6, 201.	17.1	607
35	Methylation Landscape: Targeting Writer or Eraser to Discover Anti-Cancer Drug. Frontiers in Pharmacology, 2021, 12, 690057.	3.5	5
36	Clinical Correlations of Polycomb Repressive Complex 2 in Different Tumor Types. Cancers, 2021, 13, 3155.	3.7	14

#	Article	IF	CITATIONS
37	Development of Machine Learning Models for Accurately Predicting and Ranking the Activity of Lead Molecules to Inhibit PRC2 Dependent Cancer. Pharmaceuticals, 2021, 14, 699.	3.8	4
38	An update of new small-molecule anticancer drugs approved from 2015 to 2020. European Journal of Medicinal Chemistry, 2021, 220, 113473.	5.5	27
39	Co-occurrence of immature T-lymphoblastic lymphoma and acute myeloid leukemia—microenvironment-dependent lineage differentiation derived from a common progenitor?. Journal of Hematopathology, 2021, 14, 325-332.	0.4	0
41	EZH2 is a negative prognostic biomarker associated with immunosuppression in hepatocellular carcinoma. PLoS ONE, 2020, 15, e0242191.	2.5	20
42	Polycomb and Trithorax Group Proteins: The Long Road from Mutations in Drosophila to Use in Medicine. Acta Naturae, 2020, 12, 66-85.	1.7	12
43	An overview of the development of EED inhibitors to disable the PRC2 function. RSC Medicinal Chemistry, 2022, 13, 39-53.	3.9	8
44	Cellular Origins of EGFRâ€Ðriven Lung Cancer Cells Determine Sensitivity to Therapy. Advanced Science, 2021, 8, e2101999.	11.2	13
46	VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives. European Journal of Medicinal Chemistry, 2022, 227, 113906.	5.5	27
47	Improving TRAIL-induced apoptosis in cancers by interfering with histone modifications. , 2020, 3, 791-803.		0
48	Diverse, Potent, and Efficacious Inhibitors That Target the EED Subunit of the Polycomb Repressive Complex 2 Methyltransferase. Journal of Medicinal Chemistry, 2021, 64, 17146-17183.	6.4	20
49	Hypo-trimethylation of Histone H3 Lysine 4 and Hyper-tri/dimethylation of Histone H3 Lysine 27 as Epigenetic Markers of Poor Prognosis in Patients with Primary Central Nervous System Lymphoma. Cancer Research and Treatment, 2022, 54, 690-708.	3.0	5
50	A Chemical Strategy toward Novel Brain-Penetrant EZH2 Inhibitors. ACS Medicinal Chemistry Letters, 2022, 13, 377-387.	2.8	10
51	A novel screening strategy to identify histone methyltransferase inhibitors reveals a crosstalk between DOT1L and CARM1. RSC Chemical Biology, 2022, 3, 456-467.	4.1	3
52	The New Treatment Methods for Non-Hodgkin Lymphoma in Pediatric Patients. Cancers, 2022, 14, 1569.	3.7	4
53	Tazemetostat: EZH2 Inhibitor. Journal of the Advanced Practitioner in Oncology, 2022, 13, 158-163.	0.4	47
54	Targeting key proteins involved in transcriptional regulation for cancer therapy: Current strategies and future prospective. Medicinal Research Reviews, 2022, 42, 1607-1660.	10.5	20
60	Targeting Enhancer of Zeste Homolog 2 for the Treatment of Hematological Malignancies and Solid Tumors: Candidate Structure–Activity Relationships Insights and Evolution Prospects. Journal of Medicinal Chemistry, 2022, 65, 7016-7043.	6.4	10
62	LncRNA GAS5 promotes epilepsy progression through the epigenetic repression of miR-219, in turn affecting CaMKIIγ/NMDAR pathway. Journal of Neurogenetics, 2022, 36, 32-42.	1.4	6

CITATION REPORT

CITATION REPORT

#	Article	IF	CITATIONS
63	Astronauts Plasma-Derived Exosomes Induced Aberrant EZH2-Mediated H3K27me3 Epigenetic Regulation of the Vitamin D Receptor. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	0
64	Synthetic Approaches to the New Drugs Approved During 2020. Journal of Medicinal Chemistry, 2022, 65, 9607-9661.	6.4	18
65	Long non-coding RNA SNHG1 promotes bladder cancer progression by upregulating EZH2 and repressing KLF2 transcription. Clinics, 2022, 77, 100081.	1.5	6
66	ctDNA Is Useful to Detect Mutations at Codon 641 of Exon 16 of EZH2, a Biomarker for Relapse in Patients with Diffuse Large B-Cell Lymphoma. Cancers, 2022, 14, 4650.	3.7	Ο
67	Histone Deacetylase and Enhancer of Zeste Homologue 2 Dual Inhibitors Presenting a Synergistic Effect for the Treatment of Hematological Malignancies. Journal of Medicinal Chemistry, 2022, 65, 12838-12859.	6.4	12
68	EZH2 inhibitor DZNep blocks cell proliferation of GCB-DLBCL cells by upregulating p16. Leukemia and Lymphoma, 0, , 1-8.	1.3	Ο
69	Discovery of cysteine-targeting covalent histone methyltransferase inhibitors. European Journal of Medicinal Chemistry, 2023, 246, 115028.	5.5	2
70	Cell differentiation modifies the p53 transcriptional program through a combination of gene silencing and constitutive transactivation. Cell Death and Differentiation, 2023, 30, 952-965.	11.2	3
71	MiR-124-3p inhibits tumor progression in prostate cancer by targeting EZH2. Functional and Integrative Genomics, 2023, 23, .	3.5	2
			(
72	Targeted therapy. , 2023, , 205-411.		Ο
72 73	Targeted therapy. , 2023, , 205-411. Protein posttranslational modifications in health and diseases: Functions, regulatory mechanisms, and therapeutic implications. MedComm, 2023, 4, .	7.2	0
72 73 74	Targeted therapy., 2023, 205-411.         Protein posttranslational modifications in health and diseases: Functions, regulatory mechanisms, and therapeutic implications. MedComm, 2023, 4, .         Epigenetics in myeloproliferative neoplasms. Frontiers in Oncology, 0, 13, .	7.2 2.8	0 17 0
72 73 74 75	Targeted therapy., 2023,, 205-411.         Protein posttranslational modifications in health and diseases: Functions, regulatory mechanisms, and therapeutic implications. MedComm, 2023, 4, .         Epigenetics in myeloproliferative neoplasms. Frontiers in Oncology, 0, 13, .         Integrative Multi-Omics Analysis of Oncogenic EZH2 Mutants: From Epigenetic Reprogramming to Molecular Signatures. International Journal of Molecular Sciences, 2023, 24, 11378.	7.2 2.8 4.1	0 17 0 3
72 73 74 75 76	Targeted therapy., 2023,, 205-411.Protein posttranslational modifications in health and diseases: Functions, regulatory mechanisms, and therapeutic implications. MedComm, 2023, 4, .Epigenetics in myeloproliferative neoplasms. Frontiers in Oncology, 0, 13, .Integrative Multi-Omics Analysis of Oncogenic EZH2 Mutants: From Epigenetic Reprogramming to Molecular Signatures. International Journal of Molecular Sciences, 2023, 24, 11378.HSV-1 exploits host heterochromatin for nuclear egress. Journal of Cell Biology, 2023, 222, .	7.2 2.8 4.1 5.2	0 17 0 3
72 73 74 75 76 77	Targeted therapy., 2023, 205-411.Protein posttranslational modifications in health and diseases: Functions, regulatory mechanisms, and therapeutic implications. MedComm, 2023, 4, .Epigenetics in myeloproliferative neoplasms. Frontiers in Oncology, 0, 13, .Integrative Multi-Omics Analysis of Oncogenic EZH2 Mutants: From Epigenetic Reprogramming to Molecular Signatures. International Journal of Molecular Sciences, 2023, 24, 11378.HSV-1 exploits host heterochromatin for nuclear egress. Journal of Cell Biology, 2023, 222, .Design, synthesis and evaluation of EZH2-based PROTACs targeting PRC2 complex in lymphoma. Bioorganic Chemistry, 2023, 140, 106762.	7.2 2.8 4.1 5.2 4.1	0 17 0 3 4 1
<ul> <li>72</li> <li>73</li> <li>74</li> <li>75</li> <li>76</li> <li>77</li> <li>78</li> </ul>	Targeted therapy., 2023,, 205-411.Protein posttranslational modifications in health and diseases: Functions, regulatory mechanisms, and therapeutic implications. MedComm, 2023, 4, .Epigenetics in myeloproliferative neoplasms. Frontiers in Oncology, 0, 13, .Integrative Multi-Omics Analysis of Oncogenic EZH2 Mutants: From Epigenetic Reprogramming to Molecular Signatures. International Journal of Molecular Sciences, 2023, 24, 11378.HSV-1 exploits host heterochromatin for nuclear egress. Journal of Cell Biology, 2023, 222, .Design, synthesis and evaluation of EZH2-based PROTACs targeting PRC2 complex in lymphoma. Bioorganic Chemistry, 2023, 140, 106762.Epigenetic profiles of elevated cell free circulating H3.1 nucleosomes as potential biomarkers for non-Hodgkin lymphoma. Scientific Reports, 2023, 13, .	7.2 2.8 4.1 5.2 4.1 3.3	0 17 0 3 4 1
<ul> <li>72</li> <li>73</li> <li>74</li> <li>75</li> <li>76</li> <li>77</li> <li>78</li> <li>79</li> </ul>	Targeted therapy., 2023,, 205-411.         Protein posttranslational modifications in health and diseases: Functions, regulatory mechanisms, and therapeutic implications. MedComm, 2023, 4, .         Epigenetics in myeloproliferative neoplasms. Frontiers in Oncology, 0, 13, .         Integrative Multi-Omics Analysis of Oncogenic EZH2 Mutants: From Epigenetic Reprogramming to Molecular Signatures. International Journal of Molecular Sciences, 2023, 24, 11378.         HSV-1 exploits host heterochromatin for nuclear egress. Journal of Cell Biology, 2023, 222, .         Design, synthesis and evaluation of EZH2-based PROTACs targeting PRC2 complex in lymphoma. Bioorganic Chemistry, 2023, 140, 106762.         Epigenetic profiles of elevated cell free circulating H3.1 nucleosomes as potential biomarkers for non-Hodgkin lymphoma. Scientific Reports, 2023, 13, .         Dual Targeting of EZH2 Degradation and EGFR/HER2 Inhibition for Enhanced Efficacy against Burkitt〙S Lymphoma. Cancers, 2023, 15, 4472.	7.2 2.8 4.1 5.2 4.1 3.3 3.7	0 17 0 3 4 1 1 0

#	Article	IF	CITATIONS
81	Antitumor efficacy of a sequence-specific DNA-targeted γPNA-based c-Myc inhibitor. Cell Reports Medicine, 2024, 5, 101354.	6.5	0
82	A novel exosome based therapeutic intervention against neuroendocrine prostate cancer. Scientific Reports, 2024, 14, .	3.3	0
83	EZH2-mediated development of therapeutic resistance in cancer. Cancer Letters, 2024, 586, 216706.	7.2	1
84	Development of a Cost-Efficient Process Toward a Key Synthetic Intermediate of the EZH2 Inhibitor PF-06821497. Organic Process Research and Development, 0, , .	2.7	0